Results mixed on Merck's new painkiller
13th Nov 2006, 15:33 GMT
The first published studies of Arcoxia, the drug that Merck & Co. hopes will take the place of its withdrawn painkiller Vioxx, are getting mixed reviews from doctors, some of whom say the results do not make a case for the medication's approval.
Results mixed on Merck's new painkiller related news:
- Docs Give Merck Painkiller Acroxia Mixed Reviews — FOXNews.com
- Results Mixed on Merck's New Painkiller — LancasterOnline - Health
- Results mixed on Merck's new painkiller (AP) — Yahoo! News: Health News
- Results mixed on Merck's new painkiller (Associated Press) — Yahoo! Health: Health News
- Results on Merck's new painkiller draw mixed reviews — azcentral.com | business
- Tests of new Merck painkiller criticized — baltimoresun.com - health & science
- Merck: New pain killer safer than Vioxx — Business and financial news - CNNMoney.com
- Merck says new drug is safer than Vioxx — Cardiology News from StratCenter.com
- Mixed reviews for Vioxx successor — MSNBC.com: Health
- Vioxx-Like Drug Gets Mixed Reviews — Dayton Daily News National Headlines
Latest news from CTV News RSS Feed:
- Post-9/11 laws too intrusive for some Canadians
- Bush meets with panel for talks on Iraq strategy
- Militant attacks rising in Afghanistan: report
- High-tech T-shirt turns air guitar into music
- Senior al Qaeda member captured in Afghanistan
- Bus bombing kills at least 20 in east Baghdad
- Fatah, Hamas leaders to meet over new PM
- South Korea balks at measures to sanction North
- Protesters back on streets in Bangladesh
- Medical body outlines face transplant conditions